Skip to main content
TARS
NASDAQ Life Sciences

Tarsus Q2 2026: XDEMVY Sales Surge 69% to $174M, Operating Cash Flow Turns Positive, and $125M PIPE Priced at $56

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$58.27
Mkt Cap
$2.637B
52W Low
$40.55
52W High
$85.25
52W Position info
44% above low
Off High info
32% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

TARS sits 44% above its 52-week low of $40.55 on light trading volume (0.4× avg).

Summary

Tarsus reported Q2 2026 XDEMVY net sales of $173.9M (+69% YoY), positive operating cash flow, and a $125M PIPE priced at $56 to fund recent and pending acquisitions.


Key Events · Earnings and Guidance · TARS

  • XDEMVY Sales Surge 69%

    Net product sales climbed to $173.9 million in Q2 2026, up from $102.7 million in Q2 2025, as higher prescription volumes and improved gross-to-net discounts took hold.

  • Operating Cash Flow Turns Positive

    For the first half of 2026, net cash provided by operating activities reached $36.6 million, a sharp reversal from the $50.0 million use of cash in H1 2025, underscoring robust revenue growth and disciplined working capital management.

  • Strong Liquidity Position

    Cash, cash equivalents, and marketable securities stood at $449.7 million as of June 30, 2026, offering ample runway for both operations and strategic initiatives.

  • $125M PIPE Priced at $56.00

    On August 5, 2026, a securities purchase agreement was signed for a private placement of 2.1 million shares at $56.00 per share, along with pre-funded warrants, expected to close August 7, 2026, to fund the Alkeus acquisition.


Analysis · TARS · Life Sciences

A standout quarter for Tarsus was fueled by XDEMVY net sales of $173.9 million, a 69% year-over-year leap driven by volume growth and improved gross-to-net yields. The first half of 2026 generated $36.6 million in operating cash flow—a dramatic swing from the $50 million cash burn in the prior-year period. With $449.7 million in cash and investments, the balance sheet remains strong, and the subsequent $125 million PIPE at $56 per share—a modest discount to the current $58.27—provides additional firepower for the recently closed iRenix acquisition and the pending Alkeus deal. The combination of accelerating revenue, cash flow inflection, and a well-supported M&A strategy marks a pivotal quarter.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TARS was trading at $58.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $40.55 to $85.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $77.93 info
Change: +$3.93 (+5%) info
Market Cap: $3.842B info
TARS
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.24
Real-time Price: $77.93 info
Change: +$6.69 (+9%) info
Market Cap: $3.842B info
TARS
Oct 13, 2026, 4:00 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $70.82
Real-time Price: $77.93 info
Change: +$7.11 (+10%) info
Market Cap: $3.842B info
TARS
Sep 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.12
Real-time Price: $77.93 info
Change: -$3.19 (-4%) info
Market Cap: $3.842B info
TARS
Aug 06, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $58.27
Real-time Price: $77.93 info
Change: +$19.66 (+34%) info
Market Cap: $3.842B info